Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PSNL 
Personalis Inc (PSNL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: PSNL (5-star) is a STRONG-BUY. BUY since 2 days. Simulated Profits (0.09%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.71
1 Year Target Price $10.71
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 121.63% | Avg. Invested days 28 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 952.87M USD | Price to earnings Ratio - | 1Y Target Price 10.71 |
Price to earnings Ratio - | 1Y Target Price 10.71 | ||
Volume (30-day avg) 7 | Beta 2.01 | 52 Weeks Range 2.83 - 11.40 | Updated Date 11/30/2025 |
52 Weeks Range 2.83 - 11.40 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.2763 | Actual -0.24 |
Profitability
Profit Margin -106.92% | Operating Margin (TTM) -160.68% |
Management Effectiveness
Return on Assets (TTM) -20.95% | Return on Equity (TTM) -43.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 843386654 | Price to Sales(TTM) 13.79 |
Enterprise Value 843386654 | Price to Sales(TTM) 13.79 | ||
Enterprise Value to Revenue 12.2 | Enterprise Value to EBITDA -0.03 | Shares Outstanding 88804348 | Shares Floating 52638777 |
Shares Outstanding 88804348 | Shares Floating 52638777 | ||
Percent Insiders 31.28 | Percent Institutions 57.59 |
Upturn AI SWOT
Personalis Inc
Company Overview
History and Background
Personalis, Inc. (PSNL) was founded in 2011. It focuses on advanced genomic sequencing and analysis to deliver personalized cancer therapies and diagnostics.
Core Business Areas
- Oncology: Offers comprehensive tumor and immune profiling services to biopharmaceutical companies and academic researchers to accelerate cancer research and drug development. Its flagship product is the NeXT Personal Assay.
- Pharma Services: Provides genomic data and related services for biopharmaceutical companies to support clinical trials and drug development.
Leadership and Structure
John West is the CEO. The company operates with a functional organizational structure, with departments focused on research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- NeXT Personal Assay: A comprehensive tumor and immune profiling assay used in clinical trials and research. Market share data is not publicly available. Competitors include companies offering similar comprehensive genomic profiling services such as Foundation Medicine (acquired by Roche), Guardant Health (GH), and NeoGenomics (NEO).
Market Dynamics
Industry Overview
The genomic sequencing and personalized medicine industry is rapidly growing, driven by advancements in technology and increasing demand for targeted therapies. There is increasing consolidation with larger players and a greater emphasis on data analytics.
Positioning
Personalis is positioned as a provider of advanced genomic sequencing and analysis for personalized cancer therapies. Its competitive advantages include its expertise in comprehensive tumor profiling and its focus on immuno-oncology. Increasing emphasis on solid tumor analysis is a favorable market position.
Total Addressable Market (TAM)
The TAM for cancer diagnostics and personalized medicine is estimated to be billions of dollars. Personalis is positioned to capture a portion of this market through its advanced genomic profiling services.
Upturn SWOT Analysis
Strengths
- Advanced genomic sequencing technology
- Expertise in immuno-oncology
- Strong relationships with biopharmaceutical companies
- Comprehensive tumor profiling capabilities
Weaknesses
- High operating expenses
- Reliance on a limited number of key customers
- Limited profitability
- Vulnerable to supply chain issues.
Opportunities
- Expanding applications of genomic sequencing in cancer therapy
- Increasing demand for personalized medicine
- Growth in the immuno-oncology market
- Partnerships with pharmaceutical companies
Threats
- Competition from larger genomic sequencing companies
- Regulatory changes impacting genomic testing
- Pricing pressure from payers
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Foundation Medicine (RO.SW)
- Guardant Health (GH)
- NeoGenomics (NEO)
Competitive Landscape
Personalis competes with larger, well-established companies in the genomic sequencing market. Its advantages include its comprehensive tumor profiling and focus on immuno-oncology. Disadvantages include its smaller size and limited financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been volatile, reflecting the early stage of the personalized medicine market and competition.
Future Projections: Future growth projections depend on the success of the NeXT Personal Assay and partnerships with biopharmaceutical companies. Analyst estimates vary.
Recent Initiatives: Recent initiatives have focused on expanding partnerships and enhancing the capabilities of the NeXT Personal Assay.
Summary
Personalis is a company in the personalized medicine market specializing in genomic sequencing for cancer therapies. It has strong technology and partnerships but faces significant competition and financial challenges. Success hinges on growing adoption of its NeXT Personal Assay and strategic collaborations. The company must navigate pricing pressures and regulatory changes to sustain growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Personalis Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Mr. Christopher M. Hall | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 228 | Website https://www.personalis.com |
Full time employees 228 | Website https://www.personalis.com | ||
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.